Skip to main content
SpringerLink
Log in

Adjuvante Therapie des Mammakarzinoms

  • Chapter
Therapiehandbuch Gynäkologie und Geburtshilfe

  • 4963 Accesses

Zusammenfassung

Zeitgleich zur Reduktion der operativen Radikalität in der Behandlung des Mammakarzinoms nahm die Bedeutung adjuvanter Systemtherapien zu, welche heute eine wichtige Rolle in der Behandlung des Mamakarzinoms spielen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Goldhirsch A et al. (2009) Threshholds for threapies: highlights of the St.Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329

    Article  PubMed  CAS  Google Scholar 

  • EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  • Henderson IC (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positivive primary breast cancer. J Clin Oncol 21:976–983

    Article  PubMed  CAS  Google Scholar 

  • Bedard LB et al. (2010) Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol 7:22–36

    Article  PubMed  CAS  Google Scholar 

  • De Laurentiis M et al (2008) taxane based combinations as adjuvant chemotherapy of early breast cancer: a metaanalysis of randomized trials. J Clin Oncol 26:44–53

    Article  Google Scholar 

  • Jones S et al. (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow up of US Oncology trial 9735. J Clin Oncol 27:1177–1183

    Article  PubMed  CAS  Google Scholar 

  • Martin M et al. (2010) Adjuvant Docetaxel for high risk, node negative breast cancer. N Engl J Med 363:2200–2210

    Article  PubMed  CAS  Google Scholar 

  • Eiermann W et al. (2008) BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide followed by docetaxel in women with HER2 normal node positive early breast cancer. Breast Cancer Res Treat, Abstract 77

    Google Scholar 

  • Sparano JA et al. (2008) Weekly treatment in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671

    Article  PubMed  CAS  Google Scholar 

  • Citron ML et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primari breast cancer: first report of Intergroup trial C9741/ Cancer and Leucemia Group B Trial 9741. J Clin Oncol 21:1431–1439

    Article  PubMed  CAS  Google Scholar 

  • Hudis et al. (2005) Five year follow up of INT C9741: dose dense chemotherapy is safe and effective. Breast Cancer Res Treat 94: abstract 41

    Google Scholar 

  • Möbus V et al. (2010) Intens dose dense sequential therapy wit epirubicine, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in highrisk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874–2880

    Article  Google Scholar 

  • Trialists Group ATAC (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 9:45–53

    Article  Google Scholar 

  • The BIG1–98 Collaborative Group. (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New Engl J Med 361: 766–776

    Google Scholar 

  • Rea D et al. (2009) Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective randomized phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res, Abstract 11

    Google Scholar 

  • Bliss LM et al (2009) Disease related outcome with long term follow up: an updated analysis of the Intergroup Exemestane Study. Cancer Res, Abstract 12

    Google Scholar 

  • Jakesz R et al. (2005) Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M et al. (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25: 2664–2670

    Article  PubMed  CAS  Google Scholar 

  • Goss PE et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1–10

    Article  Google Scholar 

  • Goss PE et al. (2005) Randomized trial of Letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    Article  PubMed  CAS  Google Scholar 

  • Goss PE et al. (2010) Analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastzroziole in postmenopausal women with hormone receptor positive primary breast cancer. Cancer Res 70 (24suppl) Abstract S1–1

    Article  Google Scholar 

  • Cuzick J (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet 369:1711–1723

    Article  PubMed  CAS  Google Scholar 

  • Gnant M et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 360:679–691

    Article  PubMed  CAS  Google Scholar 

  • Love RR et al. (2003) HER2-neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453–457

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  • Marty et al. (2005) Efficacy and safety of Trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:results of a randomized phase II trial by the M77001 study group. J Clin Oncol 23:4265–4274

    Article  Google Scholar 

  • Romond EH , et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable Her-2 positive breast cancer. N Engl J Med 353:1673–1684

    Article  PubMed  CAS  Google Scholar 

  • Perez E et al. (2009) Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 69 (Suppl), Abstract

    Google Scholar 

  • Slamon D et al. (2009) BCIRG 006 Phase 3 trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in the adjuvant treatment of HER2 -amplified early breast cancer patients. Cancer Res Abstract

    Google Scholar 

  • Smith I et al. (2007) 2-year follow up of trastuzumab after adjuvant chemotherapy in HER2-positicve breast cancer: a randomized controlled trial. Lancet 369:29–36

    Article  PubMed  CAS  Google Scholar 

  • Joensuu H et al. (2009) Fluorouracil, epirubicin, cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab as adjuvant treatments for breast cancer: final results of the FinHER trial. J Clin Oncol 27:5685–5692

    Article  PubMed  CAS  Google Scholar 

  • Spielmann M et al (2009) trastuzumab for patients with axillary node-positive breast cancer:results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129–6134

    Article  Google Scholar 

  • Tan-Chiu E et al. (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive human epidermal growth factor receptor 2-overexpressing breast cancer:NSABP-B31. J Clin Oncol 23:7811–7819

    Article  PubMed  CAS  Google Scholar 

  • Geyer CE et al (2006) Lapatinib plus capecitabine for HER2 positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  Google Scholar 

  • Fisher B et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685

    PubMed  CAS  Google Scholar 

  • Gianni L et al. (2009) Phase III-trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate and fluorouracil as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27:2474–2481

    Article  PubMed  CAS  Google Scholar 

  • Bear HD et al. (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvanz Breast and Bowel Project protocol B-27. J Clin Oncol 24:2019–2027

    Article  PubMed  CAS  Google Scholar 

  • Von Minckwitz G et al. (2010) Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28:2015–2023

    Article  Google Scholar 

  • Huober J et al. (2010) Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the Gepar-Trio study. Breast Cancer res 124: 133–140

    Article  CAS  Google Scholar 

  • Untch M et al. (2010) Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the Geparquinto study (GBG44). Cancer Res 70(24suppl): Abstract S3–1

    Google Scholar 

  • Gianni L et al. (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast cancer (the NOAH trial) a randomised controlled superiority trial with a parallel HER2- negative cohort. Lancet 375:377–384

    Article  PubMed  CAS  Google Scholar 

  • Baselga J et al (2010) First results of the NeoALTTO trial (BIG 01–06/EGF106903): a phase III randomized open label neoadjuvant study of lapatinib, trastuzumab and their combination plus paclitaxel in women with Her2-positive primary breast cancer. Cancer Res 70 (24 Suppl): Abstract S3–3

    Article  Google Scholar 

  • Gianni L et al (2010) Neoadjuvant pertuzumab and trastuzumab: antitumor and safety analysis of a randomized phase II study (NeoSphere). Cancer Res 70 (24 Suppl): Abstract S3–2

    Google Scholar 

  • Braun S et al. (2005) A pooled analysis of bone marrow micro-metastasis in breast cancer. N Engl J Med 353:793–802

    Article  PubMed  CAS  Google Scholar 

  • Huober J et al. (2010) Bone targeted therapy in breast cancer: present and future. Crit Rev Oncol Hematol 74(S1): 7–10

    Article  Google Scholar 

  • Gnant M et al (2010) The antitumor effect of bisphosphonates ABCSG-12, ZO-FAST and more. Crit Rev Oncol Hematol 74(S1): 2–6

    Article  Google Scholar 

  • Coleman RE et al. (2010) Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG01-04). Cancer Res 70 (24 Suppl): Abstract S4–5

    Article  Google Scholar 

  • Jörger M et al. (2010) Small HER2-positive, node negative breast cancer: who should receive systemic adjuvant treatment. Ann Oncol 22:17–23

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikum der Heinrich-Heine-Universität, Düsseldorf Frauenklinik, Bereich konservative Gynäkologische Onkologie, Moorenstraße 5, 40225, Düsseldorf

    Prof. Dr. med. Jens Huober

Authors
  1. Prof. Dr. med. Jens Huober
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fürst-Stirum-Klinik Bruchsal, Frauenklinik, Gutleutstraße 1–14, 76646, Bruchsal

    Jürgen Wacker

  2. Praxisklinik am Rosengarten, Augustaanlage 7–11, 68165, Mannheim

    Martin Sillem

  3. Praxisklinik am Rosengarten, Augustaanlage 7–11, 68165, Mannheim

    Gunther Bastert

  4. Universitätsklinikum Erlangen-Nürnberg, Frauenklinik, Universitätsstraße 21–23, 91054, Erlangen

    Matthias W. Beckmann

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Huober, J. (2013). Adjuvante Therapie des Mammakarzinoms. In: Wacker, J., Sillem, M., Bastert, G., Beckmann, M. (eds) Therapiehandbuch Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-30189-6_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-30189-6_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-30188-9

  • Online ISBN: 978-3-642-30189-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation